/ RIVERVEST NEWS
RiverVest is a leading venture capital firm building life science companies
to address significant unmet needs of patients and deliver consistently strong returns to investors.
/ PORTFOLIO COMPANY NEWS
Sparrow Appoints Biopharmaceuticals Industry Veteran, Carlo Incerti, M.D. to its Board of Directors – 2/2/2026
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease – 1/26/2026
U.S. FDA Grants to Wugen’s WU-CART-007 Breakthrough Therapy Designation for Treatment of Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia/T Cell Lymphoblastic Lymphoma – 1/21/2026
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates – 1/8/2026
Sparrow Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Clofutriben for Difficult-to-Control Type 2 Diabetes – 1/6/2026
RiverVest strives to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation.
Contact us at info@rivervest.com
Transparency in Coverage Rule: To access the machine-readable files created and published by United Healthcare, please click here.
© Copyright 2026 RiverVest® All Rights Reserved. | Privacy Policy | Accessibility Statement
Subscribe to our newsletter